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Theserotonintransporter-linkedpromoterregion(5-HTTLPR)polymorphismoftheserotonintransportergeneisassociatedwith
amygdala response during negative emotion. The aim of this study was to investigate whether this genotype effect on amygdala
function is mediated by current serotonin transporter (5-HTT) levels or rather by genetically induced inﬂuences during
neurodevelopment, shaping brain structure. A total of 54 healthy subjects underwent functional and structural magnetic
resonance imaging, [
11C]DASB positron emission tomography and 5-HTTLPR genotyping to analyze the interrelationships
between amygdala activation during processing of unpleasant stimuli, 5-HTTLPR genotype, amygdala volumes and 5-HTT levels
in the midbrain and in other brain regions. In line with previous research, carriers of the short allele (S) showed increased
amygdala activation. Path analysis demonstrated that this genotype effect was not procured by current 5-HTT availability but by
amygdala structure, with smaller amygdala volumes in the S than in the LL genotype, as well as smaller volumes being
associated with increased amygdala activation. Our ﬁndings stress the role of genetic effects during neurodevelopment.
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Introduction
Serotonin (5-HT) neurotransmission has a key role in stress
sensitivity and in vulnerability to negative affect.
1,2 The
serotonin transporter gene (SLC6A4) encodes the serotonin
transporter protein (5-HTT), which acts as a key regulator by
removing serotonin from the synaptic cleft. A variation in the
promoter region of SLC6A4, serotonin transporter-linked
promoter region (5-HTTLPR), inﬂuences its transcriptional
activity andregulates 5-HTT expressionand density inhuman
cell lines.
1,3,4 The 5-HTTLPR is a repeat polymorphism
with long (L) and short (S) alleles. The S allele is associated
with lower 5-HTT expression and function, as well as anxiety
and negative mood in healthy individuals.
3 The recently
discovered A/G single-nucleotide polymorphism (rs25531)
within the length polymorphism led to the distinction between
the variants LA and LG, with the latter one found to be
functionally similar to the S allele.
5,6 As the rs25531 G allele is
almost always in phase with the L allele,
7 5-HTTLPR is often
considered a triallelic polymorphism (LA,L G and S).
Besides the intense study of the interplay between the
5-HTTLPR and stress-reactive phenotypes like depression,
anxiety and substance use, the study of endophenotypes like
neural activation has gained great scientiﬁc interest in this
context. Previous functional magnetic resonance imaging
(fMRI) studies consistently demonstrated that carriers of the
S allele show augmented amygdala response to salient
environmental stimuli, particularly unpleasant stimuli indicat-
ing increased stress sensitivity.
8–13 So far, however, it is
not clear how this genotype effect on amygdala function is
mediated. One plausible mechanism could be through in vivo
5-HTT levels (as depicted in the model in Figure 1), which
were shown to be negatively associated with amygdala
activity.
14 However, imaging studies investigating the asso-
ciation between 5-HTTLPR and 5-HTT expression in vivo,
have revealed inconsistent results. In healthy LL, particularly
LALA carriers, several positron emission tomography (PET)
studies using the selective and non-competitively binding
5-HTT ligand [
11C]DASB reported increased 5-HTT avail-
ability in the midbrain,
15 putamen
16 and caudate.
17 Using the
tracer [
123I]b-CIT, one single photon emission computed
tomography study found increased 5-HTT availability in the
midbrainofhealthyLLcarriers,
18whichwerelaterall shownto
be carriers of two LA alleles.
15 Another [
123I]b-CIT single
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www.nature.com/tpphoton emission computed tomography study reported equal
5-HTT levels in homozygous S- and L-allele carriers, which
were increased in comparison with heterozygotes.
19 Other
single photon emission computed tomography and PET
studies using the ligands [
123I]b-CIT, [
11C]McN5652 and
[
11C]DASB have found no signiﬁcant association between
5-HTTLPR and 5-HTT.
20–24 These inconsistencies partly
reﬂect that, beyond the genetic impact, 5-HTT levels are
affected by numerous additional factors, including environ-
mental inﬂuences like daylight,
17,25 stress,
26 alcohol and
tobacco,
18,27,28 and parameters such as sex and age.
28–30
Furthermore, methodological differences between the
studies might explain discrepant results. For example, some
radioligands such as [
123I]b-CIT compete with serotonin for
binding to 5-HTT
31, whereas others such as [
11C]DASB
do not.
In addition or alternatively, the association between the
5-HTTLPR polymorphism and amygdala function could be
mediated by genetic effects on neurodevelopment, which
shapes the structure and function of brain regions critical for
negative emotion processing
10,12 (Figure 1). In line with
this, the genetically driven loss of 5-HTT function in 5-HTT
knockout mice led to morphological alterations in the
basolateral amygdala.
32 Healthy S-allele carriers may not
only show increased amygdala response to emotional stimuli
but also reduced amygdala volume.
12,33 Smaller amygdala
volume and increased amygdala response to emotional
stimuli are also observable in unmedicated patients with
depression,
34–36 although those structural alterations do not
necessarily drive functional amygdala reactivity.
12
Our multimodal study aimed to elucidate whether the
polymorphic effect of the serotonin transporter gene on
amygdala function is mediated by its inﬂuence on in vivo
5-HTT and/or amygdala structure. Thus, for the ﬁrst time,
we determined 5-HTTLPR and measured amygdala reactivity
and amygdala volumes using fMRI and structural MRI and
in vivo 5-HTT availability using [
11C]DASB PET in the same
individuals. We were furthermore interested in the effect of
nicotine dependence and therefore investigated both non-
smokers and smokers. We hypothesized that (1) 5-HTTLPR
would be associated with 5-HTT levels, with S-allele carriers
showing lower 5-HTT levels in vivo, and that this effect would
explain the polymorphic effect on amygdala reactivity
(increased amygdala activation in S-allele carriers). Conse-
quently, and in line with a previous study, we furthermore
expected to ﬁnd a negative association between 5-HTT levels
and amygdala reactivity.
14 We additionally hypothesized that
(2) S-allele carriers would show decreased amygdala
volumes and that these structural alterations might further-
more contribute to increased amygdala reactivity. With regard
to nicotine dependence, we hypothesized that chronic
smoking might elevate 5-HTT availability,
28 thereby interfer-
ing with the 5-HTT genotype.
Materials and methods
Participants. A total of 54 healthy individuals were included
in the ﬁnal sample (29 males and 25 females); see below for
exclusion criteria. The sample consisted of 29 non-smokers
and 26 smokers. Participants were 41.6±7.9 (mean±s.d.)
years of age (range: 30–59). They provided informed, written
consent according to the Declaration of Helsinki. The local
ethics committee and the Federal Ofﬁce for Radiation
Protection approved the study. Participants were recruited
by public announcement.
The Munich-Composite International Diagnostic Inter-
view
37 was used to assess axis 1 mental disorders. Exclusion
criteria were pregnancy, a lifetime history of alcohol and other
substance use disorders (except nicotine dependence for
smokers), schizophrenia, bipolar disorder or 12 months
prevalence of any other axis I disorder. Non-smokers had
smoked a maximum of 20 cigarettes in their lives, but none
during the past 12 months. All smokers fulﬁlled the DSM IV
(Diagnostic and Statistical Manual of Mental Disorders-IV)
criteria for nicotine dependence. They had a Fagerstrøm Test
for Nicotine Dependence score of 6.2±1.7 (mean±s.d.) and
hadsmoked24.5±6.6(mean±s.d.)cigarettesperdayduring
the past 3 months. A urine test for illicit drug use and for
pregnancy was applied. Participants were not taking any
medication regularly and declared not to have taken any
medication and not to have consumed any alcohol 3 days
before the experiment. All participants were right handed
(laterality quotient in the Edinburgh Handedness Inventory
38
4þ50) and had a sufﬁcient visual acuity (binocular
(corrected) X0.8).
In all, 12 of the initial 66 participants were excluded from the
study because (1) they did not pass thorough screening (and
consequently did not undergo brain imaging and blood
sampling) (n¼4), because of (2) excessive head movement
during the functional and/or structural MRI scan (n¼5) or
because of withdrawn consent in the course of the study
(n¼3). Non-smokers had participated in another study
investigating the effects of nicotine on emotional and
motivational processing.
39 Those participants underwent
two fMRI scans within 2 weeks receiving a nicotine gum in
Figure 1 Model of association between 5-HTTLPR, 5-HTT availability and
amygdalareactivity. Previous studiesindicate that the genotypeeffect on amygdala
reactivity (that is, increased amygdala reactivity in S-allele carriers) is mediated by
5-HTTand/orneurodevelopmentallyinducedeffectsonbrainstructureandfunction.
However, although reduced 5-HTT availability has been associated with increased
amygdala activation, ﬁndings on the association between 5-HTTLPR and 5-HTT
availability have been controversial, as indicated by the dotted line arrow.
Inconsistent results might be due to the inﬂuence of environmental factors like
daylight, stress and smoking on 5-HTT availability.
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Translational Psychiatryone session and a placebo gum in the other session in a
randomized order. For analysis of the current study, the fMRI
data from the placebo session were used. Although we think
that it is unlikely that a single dose of nicotine alters 5-HTT
availability in a persistent manner, a potential confound of our
data could be the administration of a 2-mg nicotine gum in an
additional fMRI session, which preceded the PET scan in 26
non-smokers. In those cases, the time lag between nicotine
application and PET scan was 8.4±5.4 (mean±s.d.) days
(range: 3–28 days). Notably, it was not associated with 5-HTT
availability in the midbrain (r¼ 0.03, P¼0.89).
The time difference between fMRI and PET scans was
9.8±10.5(mean±s.d.)days(range:1–52days).Participants
completed the German version of the state-trait anxiety
inventory.
40 They scored 28.9±4.7 (mean±s.d.; range:
21–41) on the state anxiety subscale and 30.8±6.6
(mean±s.d.; range: 20–51) on the trait anxiety subscale.
Genotyping. DNA was isolated from whole blood by
standard techniques. 5-HTTLPR variants were determined
with PCR techniques. PCR ampliﬁcation of 5-HTTLPR
was as follows: in a total volume of 20ml, B25ng of
genomic DNA was ampliﬁed with the primers as reported
previously:
7 forward 50-TCCTCCGCTTTGGCGCCTCTTCC-
30 and reverse 50-TGGGGGTTGCAGGGGAGATCCTG-30,i n
the presence of 1  Promega PCR Master Mix (Promega
Corporation, Madison, WI, USA), without multiplexing. PCR
conditions were: 5min at 951C, followed by 35 cycles of 30s
at 951C, 90s at 701C, 60s at 721C, and a ﬁnal extension of
10min at 721C. Detection of rs25531 by restriction digest
was performed as follows: 20ml PCR product was digested
with 10Units HpaII (New England BioLabs, Ipswich, MA,
USA) for 4h at 371C. Samples were run on 3% agarose gel
and precast stained with GelRed (Biotium, Hayward, CA,
USA). To score the genotypes, undigested and digested
PCR products of the same sample were run on adjacent
lanes as described previously.
7
Functional magnetic resonance imaging
Task. Affectively unpleasant, pleasant and neutral pictures
from the International Affective Picture System
41 were used
to elicit amygdala activation during fMRI. For each category,
40 slides were presented for 2000ms in an individually
randomized order using an event-related design. The
inter-trial interval was randomized between 2.0 and 9.9s
(mean 6.0s). During the inter-trial interval, a ﬁxation cross
was presented. Participants were instructed to passively
view the stimuli, as even simple rating tasks can alter brain
activation.
42 To control for attention, a recognition memory
test was conducted inside the scanner directly after the scan.
The scanning time was 16min and 40s. For further details,
see our previous publications.
39,43
fMRI data acquisition and analysis. Scanning was performed
using a 3-T whole-body MRI scanner (Magnetom TRIO;
Siemens, Erlangen, Germany) equipped with a standard
head coil. For functional imaging, a standard echo planar
image (EPI) sequence was used (repetition time¼2410ms;
echo time)¼25ms; ﬂip angle: 801). fMRI scans were
obtained from 42 transversal slices, orientated 301
clockwise to the anterior commissure-posterior commissure
line, with a thickness of 2mm (1-mm gap), a ﬁeld of view of
192 192mm and an in-plane resolution of 64 64 pixels,
resulting in a voxel size of 3 3 2mm. Images were
presented through goggles using MRI Audio/Video Systems
(Resonance Technology, Northridge, CA, USA). Task
presentation was performed using Presentation (Version
9.90, Neurobehavioral Systems, Albany, CA, USA).
Data were analyzed with Statistical Parametric Mapping
(SPM5; Wellcome Department of Imaging Neuroscience,
London, UK). Before data analysis, functional data underwent
preprocessing. The ﬁrst ﬁve images were discarded to reduce
T1 saturation effects. Data were temporally realigned with
descending slice order to minimize temporal differences in
sliceacquisition.Spatialrealignmentwasperformedtocorrect
for head motion over the course of the session. Functional
data were normalized to a standard EPI template, resampled
with a voxel size of 2 2 2mm and smoothed using an
isotropic Gaussian kernel (8mm full-width at half-maximum).
On an individual level, different conditions (such as
pleasant, unpleasant and neutral pictures) were modeled as
explanatory variables within the context of the general linear
model on a voxel-by-voxel basis. Time derivatives were
included in the model to account for temporal differences in
the peak of the hemodynamic response.
To interrelate amygdala activation with 5-HTTLPR, 5-HTT
and amygdala volume, we extracted the mean signal change
from the individual contrast images unpleasant-neutral stimuli
applying a bilateral amygdala mask (left amygdala: 161
voxels, right amygdala: 158 voxels) provided by the WFU
Pickatlas (Department of Radiology, Wake Forest University
School of Medicine, Winston-Salem, NC, USA). To demon-
strate that unpleasant versus neutral stimuli elicit signiﬁcant
amygdala activation, we calculated one-sample t-tests
using SPSS (PASW Statistics 17, SPSS Inc., Chicago, IL,
USA). To additionally illustrate the main effects of the task at
thewhole brainlevel,weperformedasecond-levelvoxel-wise
random-effects full factorial analysis with the factor condition
(unpleasant, pleasant, neutral). We applied a threshold of
Po0.01, corrected for family-wise error, with a minimum
cluster size of n¼20 adjacent voxels. For explorative
purposes, we also extracted the mean amygdala signal
change from the individual contrast images pleasant-neutral
stimuli and unpleasant-pleasant stimuli.
Structural MRI data acquisition and analysis. For analysis
of brain volume, a three-dimensional T1-weighted
magnetization-prepared rapid gradient echo image data
set was acquired (repetition time¼1900ms, echo
time¼2.26ms, ﬁeld of view¼256 256mm, 176 slices,
1 1 1mm voxel size, ﬂip angle¼91). The scanning time
for the magnetization-prepared rapid gradient echo was
5min 59s. To measure the volumes of the left and right
amygdala, masks of the amygdala structure were created
using the automated, model-based, segmentation tool FIRST
of FMRIB’s Software Library.
44,45 To account for differences
in head sizes, total intracranial volume was measured using
FreeSurfer (Martinos Center for Biomedical Imaging,
Charlestown, MA, USA)
46,47 and used as a covariate in the
analysis.
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PET data acquisition and analysis. [
11C]DASB was
synthesized as described previously.
48 After an intravenous
bolus injection of 20mCi [
11C]DASB, cerebral radioactivity
distribution was measured over 90min using a GE Advance
PET scanner (GE Medical Systems, Milwaukee, WI, USA)
in two-dimensional acquisition mode. For attenuation
correction, a transmission scan with 500.000 kilocounts was
used. Three external markers had been attached to the skull
to support realignment. Filtered backprojection (128 128
pixel¼30cm) with a Hanning ﬁlter (cutoff 4.6mm) was
used to reconstruct images. Images were realigned and
stereotactically normalized with Matlab (Version 7,
MathWorks, Sherborn, MA, USA) and SPM2 (Wellcome
Department of Imaging Neuroscience). For stereotactic
normalization, early summation images (0–5min p.i.) were
compared with the standard PET perfusion template provided
by SPM. Three-dimensional regions of interest for the
midbrain, thalamus, amygdala and cerebellum were taken
from previous studies with [
11C]DASB.
15,26 Although the
thalamus, amygdala and cerebellum have been deﬁned
manually in Montreal Neurological Institute (MNI) space
upon anatomical criteria, the midbrain region of interest has
been created for [
11C]DASB PET studies by applying an
isocontour threshold of BPND42.5 to a group of healthy
subjects. 5-HTT-binding potential BPND¼k3/k4¼fND Bmax/
KD (fND¼free fraction in the ﬁrst tissue compartment;
Bmax¼concentration of binding sites, that is, serotonin
transporters; KD¼dissociation constant) was calculated for
each voxel with the multilinear reference tissue model 2.
49
The washout from the reference tissue k2R, which is required
for this analysis, was estimated as described previously.
15
Statistical analysis. Data were analyzed using SPSS.
The threshold of statistical signiﬁcance was set at Po0.05.
Those hypotheses which were directed because of
consistent ﬁndings from previous studies were tested
one-tailed; all others two-tailed. We grouped heterozygous
and homozygous S-allele carriers together (LL¼LALA;
S0 ¼LALG/LAS/SS/LGS/LGLG). LL-allele carriers were coded
with 0, and S-allele carriers with 1.
Bivariate correlations were conducted to replicate ﬁndings
of an association between 5-HTTLPR and amygdala activa-
tion to unpleasant stimuli and to display relationships among
5-HTTLPR, midbrain 5-HTT availability, left and right amyg-
dala structures and left and right amygdala activations. Data
on amygdala activation elicited by pleasant-neutral stimuli
and unpleasant-pleasant stimuli and their associations with
5-HTTLPR, 5-HTT availability and amygdala volume are
presented in Supplementary Figure S1 and in Supplementary
Table S1. Moreover, state and trait anxiety scores were
associated with 5-HTTLPR, 5-HTT availability, amygdala
volumes and activations (Supplementary Table S1).
Path analyses using SPSS AMOS 17 (Analysis of Moment
Structures; IBM Corporation, Somers, NY, USA) were
conducted to test our a priori model of the role of 5-HTT
availability and amygdala structure in mediating the relation-
ship between 5-HTTLPR and amygdala activation. The path
model (Figure 3)comprised connections between5-HTTLPR,
midbrain 5-HTT availability, left and right amygdala structures
and left amygdala activation. In the model, 5-HTTLPR has
direct effects on left amygdala activation, bilateral amygdala
volumes and midbrain 5-HTT availability and has indirect
effects on left amygdala activation through midbrain 5-HTT
availability and bilateral amygdala volumes. Moreover, 5-HTT
availability andbilateral amygdalavolumes havedirect effects
on left amygdala activation. To further explore the inﬂuence of
smoking status and to control for the inﬂuences of covariates,
further analyses were conducted: a multi-group analysis
testing for differences between smokers and non-smokers
and a path model including the covariates sex, age,
intracranial volume and state anxiety. In addition, we
calculated a path model including correlated error terms of
the left and right amygdala volumes to account for a possible
dependency of residual variances (that is, not accounted for
by the paths in the model). Signiﬁcance for all relationships
was determined at Po0.05; trends were noted at Po0.10.
Model ﬁts were assessed by w
2 goodness-of-ﬁt tests and by
root mean square error of approximations, which are two
commonindicesfordevianceofthemodelfromthedata.They
are presented in Supplementary Information.
To further investigate the relationship between 5-HTTLPR
and 5-HTT availability, to test for effects of smoking status on
5-HTT availability and to validate preliminary ﬁndings of sex
differences in 5-HTT availability and a smoking-speciﬁc
interaction of those sex differences,
28 an ANOVA (analysis
of variance) was conducted using midbrain 5-HTT availability
as a dependent variable, 5-HTTLPR, smoking status and sex
as ﬁxed factors and age as covariate.
Results
Genotype data, 5-HTT availability, amygdala volume and
amygdala activation in response to unpleasant
stimuli. Triallelic genotyping of 5-HTTLPR revealed that of
the 54 participants, 16 (29.6%) were LL, 29 (53.7%) were
S0La n d9( 1 6 . 7 % )w e r eS 0S0 (LL¼LALA;S 0L¼SLA/LALG;
S0S0 ¼SS/SLG/LGLG). Frequencies did not differ signiﬁcantly
from the Hardy–Weinberg equilibrium (w
2¼0.46; P¼0.50).
5-HTT availability was highest in the midbrain, thalamus,
amygdala and striatum (Supplementary Figure S2). Midbrain
5-HTT availability was highly associated with thalamic
5-HTT availability (r¼0.84, Po0.001) and amygdala 5-HTT
availability (r¼0.67, Po0.001). For subsequent analysis, we
used midbrain 5-HTT availability. Distributions of thalamic and
amygdala 5-HTT availability are reported in Supplementary
Table S2.
Magnetic resonance imaging volumetry showed that the
size of the left amygdala was 1266.6±280.5mm
3
(mean±s.d.) and that the size of the right amygdala was
1314.8±330.8mm
3.
The analysis of mean signal change extracted from the
bilateral amygdala showed that unpleasant compared with
neutral stimuli elicited a signiﬁcant activation in the right and
left amygdala: 0.90±0.88 (mean±s.d.; t(53)¼7.53, P¼6 
10
–10)and0.88±1.10(mean±s.d.;t(53)¼6.16,P¼1 10
–7),
respectively. The results of the voxel-wise whole-brain
analysis are displayed in Figure 2a and in Supplementary
Table S3.
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activation and the mediating role of 5-HTT availability
and amygdala volume. 5-HTTLPR was associated with left
amygdala activation in response to unpleasant stimuli
(r¼0.30, P¼0.015). The association between 5-HTTLPR
and right amygdala activation was not signiﬁcant (r¼0.16,
P¼0.129, Figure 2b). Table 1 presents bivariate correlations
between variables. Path analysis showed that 5-HTTLPR
had direct effects on bilateral amygdala volumes (left
amygdala volume: path coefﬁcient (b)¼ 0.30, P¼0.012;
right amygdala volume: b¼ 0.28, P¼0.017, one-tailed),
indicating smaller amygdalae volumes in S-allele carriers
(Figure 3). The effect of 5-HTTLPR on midbrain 5-HTT
availability was negligible. The path between right amygdala
volume and left amygdala activation was signiﬁcant
(b¼ 0.30, P¼0.010, one-tailed), indicating that individuals
with small right amygdala volumes showed increased left
amygdala activation. Notably, the direct effect of 5-HTTLPR
on left amygdala activation was no longer signiﬁcant
(b¼0.22, P¼0.053, one-tailed). No further relationships
were signiﬁcant (see Supplementary Table S4 and
Supplementary Information for a detailed account of the
path coefﬁcients). Accounting for the inﬂuences of age
and sex on midbrain 5-HTT availability, the inﬂuence of
intracranial volume on amygdala structure and the inﬂuence
of state anxiety on amygdala activation in response
to unpleasant stimuli did not signiﬁcantly alter the results
(see Supplementary Table S5 and Supplementary
Figure S3). Finally, the correlation between the error terms
of right and left amygdala volumes neither altered the pattern
of results nor signiﬁcantly improved model ﬁt (w
2¼2.202,
df¼1, P40.1). Thus, the more parsimonious model
presented in Figure 3 is to be preferred.
Association between 5-HTTLPR and 5-HTT availability
and inﬂuence of smoking status and sex. The ANOVA
testing for main effects and interactions of 5-HTTLPR,
smoking status and sex in predicting 5-HTT availability
revealed no overall differences in midbrain 5-HTT availability
between the S and the LL genotypes. Neither did we ﬁnd a
signiﬁcant inﬂuence of smoking status or sex on midbrain
5-HTT availability. However, there was an interaction
between 5-HTTLPR and smoking status (F(1,45)¼4.61;
P¼0.037) indicating increased midbrain 5-HTT availability in
non-smoking homozygote L-allele carriers compared with
smoking homozygote L-allele carriers and decreased
midbrain 5-HTT availability in non-smoking S-allele carriers
compared with smoking S-allele carriers (Figure 4 and
Supplementary Table S2). Notably, we did not ﬁnd an
interaction between smoking status and sex regarding the
availability of 5-HTT as reported previously.
28
Association between 5-HTT availability and amygdala
activation in response to unpleasant stimuli. Midbrain
5-HTT availability was not associated with left amygdala
activation (r¼ 0.001, P¼0.496). However, it was
negatively correlated with right amygdala activation
(r¼ 0.25, P¼0.037, one-tailed; partial correlation
controlling for age and sex: r¼ 0.25, P¼0.036, one-
tailed, see Supplementary Figure S4). There were no
associations between left or right amygdala activation and
5-HTT availability in other brain regions.
Discussion
To the best of our knowledge, this is the ﬁrst study that
investigated the association between 5-HTTLPR, amygdala
activation in response to unpleasant stimuli, amygdala
volumes and in vivo 5-HTT availability in the sameindividuals.
We tested whether the frequently reported genotype effect on
amygdala function
8,10,11,13 (that is, increased amygdala
activation in S-allele carriers) is mediated by in vivo serotonin
transporter (5-HTT) levels and/or by amygdala structure,
Figure 2 (a)Amygdalaactivation duringpresentation of unpleasant comparedwith neutralstimuli.Thestatisticalparametricmap was overlaidon atemplateT1-weighted
magnetic resonance image at Po0.01, corrected for family-wise error (FWE). MNI coordinates for the maximal t-score in the right and left amygdala are x¼22, y¼ 6;
z¼ 14 (cluster size: 139 voxels; t-score: 9.1) and x¼ 20; y¼ 8, z¼ 16 (cluster size: 100 voxels; t-score: 8.7), respectively. (b) Mean left and mean right amygdala
response to unpleasant compared with neutral stimuli in the LL and SS/SL genotypes of triallelic 5-HTTLPR. The S genotype carriers had a higher left amygdala response
(r¼0.29, P¼0.017) but not right amygdala response (r¼0.16; P¼0.129). Error bars indicateþ1 standard error, N¼54.
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during neurodevelopment.
As expected, S-allele carriers showed increased left
amygdala activation in response to unpleasant compared
with neutral stimuli. Contrary to our hypothesis, this genotype
effect on amygdala reactivity, however, could not be
explained by direct genotype effects on 5-HTT expression:
in the whole group, we found no association between
5-HTTLPR and 5-HTT availability. Neither was 5-HTT
availability associated with left amygdala activation. Instead,
the polymorphic effect of 5-HTTLPR on amygdala reactivity
was mediated by amygdala structure. First of all, S-allele
carriers had smaller bilateral amygdala volumes and right
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Figure 3 Path analysis predicting left amygdala activation (L Amy BOLD); path
coefﬁcients: 5-HTTLPR (triallelic), 5-HTT availability midbrain (5-HTT Mid), left and
right amygdala volumes (L Amy Vol, R Amy Vol). Signiﬁcant paths are depicted
in bold lines.
Figure 4 Interaction between 5-HTTLPR and smoking status: non-smoking LL
genotype carriers showed increased midbrain 5-HTT levels compared to non-
smoking S genotype carriers, whereas the reverse effect was found in smokers
(interaction between5-HTTLPR and smoking status:F(1,45)¼4.61; P¼0.037).In
the whole group midbrain 5-HTT availability did not differ between LL and S
genotypes. Error bars indicate±1 standard error.
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smaller volumes being associated with higher activations.
Furthermore, in our path model, the direct effect of 5-HTTLPR
on amygdala activation was no longer signiﬁcant. Although
decreased amygdala volume and increased amygdala
response have been reported in healthy S-allele carriers, as
well as in unmedicated patients with depression,
8,10,12,36 a
direct association between amygdala volume and amygdala
response to emotional stimuli has so far only been demon-
strated in adolescents with bipolar disorder.
50 In line with our
data, the association was inverse in this study. A possible
mechanism discussed in the literature and potentially explain-
ingourﬁndingistheeffectof5-HTTLPRpolymorphicvariation
on neurodevelopment, which shapes the structure and
function of brain regions critical for negative emotion proces-
sing. Thus, it is possible that 5-HTTLPR exerts an early
neurodevelopmental inﬂuence on amygdala structure, which
translates the polymorphic variation into the endophenotype
‘amygdala reactivity’. This neurodevelopmental view is
supported by studies with 5-HTT knockout mice and rats
and with mice and rats prenatally exposed to selective
serotonin reuptake inhibitors (SSRI), who both exhibit
increased extracellular serotonin levels.
51 Those studies
show that 5-HTT blockade during early development caused
alterations in the morphology of pyramidal neurons in the
amygdala
32 and increased anxiety and depression which
persisted into adulthood (opposing the effects induced by
adult SSRI intake).
52,53 It is argued that those behavioral and
morphological effects are similar to the effects of the S-allele
of the 5-HTTLPR polymorphism.
Notably, amygdala volumes did not explain the entire
genotype effect on amygdala response to unpleasant stimuli
as indicated by the path between 5-HTTLPR and amygdala
activation, which showed a weakened (and no longer
signiﬁcant) but not an entirely vanished association. There-
fore, it is likely that additional mediators which we did not
capture in our model are involved, such as volumes of
other brain structures and/or connections between different
brain structures.
In line with previous studies,
10,13 the association between
5-HTTLPR and amygdala function was condition speciﬁc: it
was present in response to unpleasant compared with neutral
stimuli,and not in response to pleasant compared with neutral
stimuli (which also elicited pronounced amygdala activation).
In contrast to those previous studies and despite a high
correlation between left and right amygdala activations
(r¼0.70, Po0.001), 5-HTTLPR unexpectedly was not
signiﬁcantly associated with right amygdala activation. Even
more surprisingly, we found that right amygdala volume was
stronger associated with left amygdala activation than with
right amygdala activation. Interestingly, in the non-human and
human primate brains, no major interamygdaloid connections
have been found.
54,55 However, functional connectivity is
frequently observed in brain regions which are not or only
sparsely connected,
56 pointing to the mediating role of third
regions. Therefore, the high correlation of left and right
amygdala activations, which is in line with ﬁndings from a
recent meta-analysis,
57 could be mediated by a third region—
for example, the prefrontal cortex—which has strong anato-
mical and functional connections to the amygdala.
10,58 The
mediating inﬂuence of a third region might also explain our
unexpected ﬁnding of an association between right amygdala
volume and left amygdala activation. The lack of association
between left amygdala volume and left amygdala activation
might be due to insufﬁcient power. Future studies will have to
replicate our data and clarify the role of laterality.
Interestingly, the association between 5-HTTLPR and
5-HTT availability was modulated by smoking status, with
non-smokers replicating previous ﬁndings of higher 5-HTT
levels in LL genotype carriers compared with S-allele
carriers
15,16 and smokers showing opposite patterns. None
of the previous studies which found no association between
5-HTTLPR and 5-HTT availability have reported smoking
status of participants, and nicotine abuse or dependence was
not an explicit exclusion criterion. Possibly, a converse
association between 5-HTTLPR and 5-HTT availability in
non-smokers and smokers can lead to a leveling out of whole
group effects. Strikingly, a [
123I]b-CIT single photon emission
computed tomography study showed increased midbrain
5-HTT availability in healthy individuals homozygous for the
L-allele compared with S-allele carriers and the inverse
relationship for alcoholic patients.
18 This and our present
ﬁnding indicate a potential role of chronic substance intake in
modulating the association between 5-HTTLPR and in vivo
5-HTT availability, which has to be further explored. With
regard to the direct effect of nicotine dependence on 5-HTT
availability, however, we could not replicate previous ﬁndings
of increased 5-HTT availability in smokers
28 as we found no
signiﬁcant differences between smokers and non-smokers.
Our ﬁnding of an inverse association between right
amygdala activity with unpleasant stimuli and midbrain
5-HTT availability complements ﬁndings from a previous
study,
14 although it was less pronounced and not replicated
for 5-HTT availability in the amygdala—despite a close
association between midbrain and amygdala 5-HTT avail-
ability.
A limitation of our study is the relatively small group of
homozygous L-allele carriers, which represents the naturally
occurring 5-HTTLPR genotype distribution. To increase
power, future studies could perform genotyping before
assignment to the imaging study to get even sample sizes of
L- and S-allele carriers. This would further allow separate
analysis of homozygous and heterozygous S-allele carriers.
The fundamental study of the interplay between serotoner-
gic and affective mechanisms in the healthy human brain is a
prerequisite for understanding the pathophysiology of mood
and anxiety disorders, as well as the effects of pharmaco-
logical treatment targeting the serotonergic system. Our
multimodal imaging genetic study indicates that the 5-
HTTLPR genotype effect on amygdala activation is procured
by amygdala structure rather than by current effects of 5-HTT
availability. Our ﬁndings suggest that the path for this genetic
effect on emotional reactivity may be paved during neuro-
development, thereby concurring with animal studies which
demonstrate that prenatal SSRI exposure is accompanied by
long-termeffectsonbrainstructureandbybehaviouraleffects
which can dramatically differ from the effects of 5-HTT
blockade during adulthood.
51 Future studies need to investi-
gate the effects of prenatal SSRI exposure on human brain
structure and function. Although more than two decades
5-HTTLPR, 5-HTTand amygdala function and volume
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Translational Psychiatryhave passed since the introduction of the ﬁrst SSRI, those
long-term consequences are completely unknown.
Furthermore, although most previous studies have
investigated 5-HTTLPR in relation to amygdala activation or
5-HTT levels, future studies need to highlight the impact
of environmental factors in this context and grasp gene–
environment interactions, such as the inﬂuence of substances
like tobacco and alcohol.
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